CLCornelia Lee

Cornelia Lee

*This is an algorithmically generated author record based on publicly available information.

Cornelia Lee has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of Quality of Life Domains and Clinical Symptoms in Patients With Familial Cerebral Cavernous Malformation

    by Cynthia Tsang, Jeffrey Nelson, Rachel Vassar, Nerissa U. Ko, Charles McCulloch, Edward R. Smith, Sudhakar Vadivelu, Amy Akers, Cornelia Lee, Joseph Zabramski, et al.

    Background: Familial cerebral cavernous malformation (fCCM) is characterized by multiple brain lesions affecting quality of life. PROMIS‐29 (Patient‐Reported Outcomes Measurement Information System 29) is a quality of life survey validated in some neurological diseases but not in fCCM. We assessed the reliability, validity, and association of PROMIS‐29 in fCCM with clinical symptoms and with the modified Rankin Scale. Methods: PROMIS‐29 surveys assessing 7 quality of life domains were completed by 198 patients with fCCM ≥18 years old in the Brain Vascular Malformation Consortium cerebral cavernous malformation study. Raw domain scores were converted to T scores standardized to a reference population (mean 50±10) and tested using intercept‐only regression ( P ≤0.05). Linear mixed models tested whether domain scores were associated with age, sex, clinical symptoms at time of first survey, or with modified Rankin Scale score. Results: PROMIS domains had high reliability (Cronbach α >0.85). Patients with fCCM reported significantly worse anxiety (52.71 [95% CI, 51.23–54.20]), pain (52.50 [95% CI, 50.93–54.07]), and physical functioning (52.96 [95% CI, 51.40–54.52]), but better social participation (46.95 [95% CI, 45.35–48.54]) versus reference. Prior intracranial hemorrhage was associated with worse anxiety (+3.11 [95% CI, 0.10–6.12]), fatigue (+3.68 [95% CI, 0.61–6.76]), physical functioning (+3.79 [95% CI, 0.74–6.84]), and social participation (+4.42 [95% CI, 1.28–7.56]). Headaches were associated with worse depression (+3.17 [95% CI, 0.18–6.17]), fatigue (+4.14 [95% CI, 0.70–7.59]), pain (+3.88 [95% CI, 0.40–7.37]), and sleep disturbance (+2.94 [95% CI, 0.03–5.85]). Modified Rankin Scale score was weakly to moderately and positively associated with all domains except sleep disturbance (0.01≤ R 2 ≤0.55). Conclusions: PROMIS domains were reliable and correlated with modified Rankin Scale score and symptoms in fCCM, identifying affected domains beyond physical functioning. Future studies should determine whether changes in health domains are associated with fCCM disease severity and further evaluate clinical usefulness of PROMIS.


  • Top Cited Papers
    Open Access

    Guidelines for the Diagnosis and Clinical Management of Cavernous Malformations of the Brain and Spinal Cord: Consensus Recommendations Based on a Systematic Literature Review by the Alliance to Cure Cavernous Malformation Clinical Advisory Board Experts Panel

    by Amy L. Akers, John Albanese, Roberto J. Alcazar-Felix, Rustam Al-Shahi Salman, Issam A. Awad, Edward S. Connolly, Amy Danehy, Kelly D. Flemming, Errol Gordon, Stephanie Hage, et al.

    BACKGROUND AND OBJECTIVES: Despite many publications about cavernous malformations (CMs), controversy remains regarding diagnostic and management strategies. To update evidence-based guidelines for the clinical management of brain and spinal cord CMs. METHODS: The Alliance to Cure CMs, the patient support group in the United States advocating on behalf of patients and research in CM, convened a multidisciplinary writing group comprising expert CM clinicians to help summarize the existing literature related to the clinical care of CM, focusing on 5 topics: (1) epidemiology and natural history, (2) genetic testing and counseling, (3) diagnostic criteria and imaging standards, (4) neurosurgical considerations, and (5) neurological considerations. Building on prior evidence-based recommendations reflecting literature review through October 2014, the group conducted a systematic review of the more recent literature, identified references for mandatory citation, rated evidence, developed recommendations, and established consensus according to a prespecified protocol. Finally, the writing group outlined remaining knowledge gaps and controversies to guide future research. RESULTS: From 2672 publications published between October 1, 2014, and March 15, 2023, and meeting key word criteria, 234 were selected based on prearticulated criteria for mandatory consideration in evidence-based recommendations. Topic authors used these and other supporting references to summarize current knowledge and arrive at 53 management recommendations, with unanimous consensus based on a Delphi process. These were rated by class (strength of recommendation) and level (quality of evidence) per the American Heart Association/American Stroke Association criteria. Eighteen recommendations were class 1 (34%), class 2 in 31 (58%), and class 3 in 4 (8%). Three were level A (6%), 19 (36%) were level B, and 31 (58%) were level C. CONCLUSION: Current evidence supports prior and new recommendations for the management of CMs, but many reflect moderate classes and low levels, mandating further research to better inform clinical practice.


  • Open Access

    Developing a Randomised Efficacy PREcision medicine Platform trial design for Cavernomas: the CARE PREP study

    by Rustam Al-Shahi Salman, Kasia Adamczuk, Richard A Parker, Christopher J Weir, Roberto Latini, Helen Kim, David White, Helen Evans, Jana Bergholtz, Cornelia Lee, et al.

    Background: Symptomatic cerebral cavernous malformations are a rare sporadic or familial disease, which may cause haemorrhagic strokes or epileptic seizures. In 2015, a James Lind Alliance Priority Setting Partnership ranked targeted drug therapies as fourth of the top 10 research priorities for cerebral cavernous malformations. There are no disease-modifying drugs for cerebral cavernous malformations, but there are several promising candidates with proof of concept in human and animal studies. There are no platform trials for cerebral cavernous malformations. Objectives: (1) Consolidate and initiate international collaborations between cerebral cavernous malformations researchers, cerebral cavernous malformations patient and public involvement groups, cerebral cavernous malformations research networks, and commercial partners; (2) Finalise a protocol for an efficient, international platform trial of multiple drugs using precision medicine (sporadic vs. familial cerebral cavernous malformations) that is both feasible and acceptable to patients and regulators; (3) Estimate the research, support and treatment costs of the platform trial and apply to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation Programme. Methods: A National Institute for Health and Care Research Efficacy and Mechanism Evaluation Application Acceleration Award funded this project from September 2022 to August 2023. A trial manager supported the Chief Investigator in growing and leading a multidisciplinary international collaboration, including a patient and public involvement advisory group, in a series of meetings to optimise study design, equality, diversity and inclusion. Edinburgh Innovations established connections with commercial partners with candidate drugs. We assessed feasibility by scoping potential funding agencies, and clinical networks that might support recruitment internationally. We agreed upon a final design and sample size through a process of consensus, enlightened by scenarios simulated by statisticians varying key parameters, which informed a comprehensive estimate of the budget for a stage 1 submission to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation programme. Setting: International collaboration. Participants: Clinicians, researchers, patient and public involvement groups, cerebral cavernous malformations research networks, and commercial partners. Results: There was one face-to-face meeting, nine virtual meetings of the co-applicants, and five meetings of the patient and public involvement advisory group. We identified 14 countries with clinical leadership, a cerebral cavernous malformation research network, and a funding agency that could support an international trial. We contacted three potential commercial partners and obtained one letter of collaboration. We sent monthly newsletters to collaborators. Our meetings and simulations concluded that a three-arm, two-stage multiarm multistage adaptive treatment selection randomised trial design was suitable for evaluating aspirin and propranolol as the first two interventions compared with standard care in a platform trial. We submitted a stage 1 proposal for this Cavernous malformations A Randomised Efficacy MAster Protocol study to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation call 23/15 in May 2023, and a resubmission was encouraged. Limitations: The National Institute for Health and Care Research Efficacy and Mechanism Evaluation funding committee would have required further justification for the choice of the intermediate phenotype used for treatment selection, biomarker validation work, and details about the pipeline of interventions. Future work: We have addressed these limitations and re-applied to the National Institute for Health and Care Research Efficacy and Mechanism Evaluation programme. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme as award number NIHR153811.


  • COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation

    by Abdallah Shkoukani, Abhinav Srinath, Agnieszka Stadnik, Romuald Girard, Robert Shenkar, Adrienne Sheline, Kristen Dahlem, Cornelia Lee, Kelly Flemming, Issam A. Awad


  • Open Access

    Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma

    by Sean P. Polster, Anukriti Sharma, Ceylan Tanes, Alan T. Tang, Patricia Mericko, Ying Cao, Julián Carrión-Penagos, Romuald Girard, Janne Koskimäki, Dongdong Zhang, et al.

    Cavernous angiomas (CA) are common vascular anomalies causing brain hemorrhage. Based on mouse studies, roles of gram-negative bacteria and altered intestinal homeostasis have been implicated in CA pathogenesis, and pilot study had suggested potential microbiome differences between non-CA and CA individuals based on 16S rRNA gene sequencing. We here assess microbiome differences in a larger cohort of human subjects with and without CA, and among subjects with different clinical features, and conduct more definitive microbial analyses using metagenomic shotgun sequencing. Relative abundance of distinct bacterial species in CA patients is shown, consistent with postulated permissive microbiome driving CA lesion genesis via lipopolysaccharide signaling, in humans as in mice. Other microbiome differences are related to CA clinical behavior. Weighted combinations of microbiome signatures and plasma inflammatory biomarkers enhance associations with disease severity and hemorrhage. This is the first demonstration of a sensitive and specific diagnostic microbiome in a human neurovascular disease.